ID: h-var-b046808f73
Hypothesis

CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL-1β Amplification and CNS Immune Privilege Breakdown

This hypothesis proposes that circulating hs-CRP directly recruits CCR2+ monocytes to the CNS through upregulation of CCL2 signaling, where these infiltrating monocytes then amplify microglial IL-1β production via the TLR4/MyD88 axis, ul.
🧬 CCR2, TLR4, IL1B🩺 immunomics🎯 Composite 38%💱 $0.46▲15.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 4 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.26 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.40 (10%) Safety 0.60 (8%) Competition 0.70 (6%) Data Avail. 0.65 (5%) Reproducible 0.55 (5%) KG Connect 0.50 (8%) 0.380 composite

🧪 Overview

This hypothesis proposes that circulating hs-CRP directly recruits CCR2+ monocytes to the CNS through upregulation of CCL2 signaling, where these infiltrating monocytes then amplify microglial IL-1β production via the TLR4/MyD88 axis, ultimately disrupting CNS immune privilege. The mechanism begins with elevated hs-CRP binding to microglial TLR4 receptors, triggering MyD88-dependent signaling that not only increases local IL-1β production but also upregulates CCL2 expression. This CCL2 gradient attracts peripheral CCR2+ monocytes across the blood-brain barrier, creating a positive feedback loop where infiltrating monocytes further enhance microglial activation and IL-1β release. The sustained presence of CCR2+ monocytes fundamentally alters the CNS immune environment, transforming the normally immunosuppressive microglial phenotype into a pro-inflammatory state that breaks down immune privilege. This dual-phase process—initial CRP-mediated microglial priming followed by monocyte-sustained amplification—explains how peripheral inflammation becomes entrenched in CNS tissue.

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Circulating hs-CRP Elevation<br/>Systemic Inflammatory Signal"]
    B["Microglial Fc/TLR4 Priming<br/>MyD88/NFkB Tone Increased"]
    C["pro-IL1B Production<br/>Inflammasome Substrate Accumulates"]
    D["NLRP3-Caspase-1 Cleavage<br/>Mature IL-1beta Release"]
    E["Feed-Forward Neuroinflammation<br/>Synaptic Stress and Neuronal Injury"]
    F["CRP Lowering or IL1B Blockade<br/>Inflammatory Amplifier Interrupted"]
    A --> B
    B --> C
    C --> D
    D --> E
    F -.->|"blunts"| D
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix4 supports4 contradicts
Supports
Patients with elevated baseline hs-CRP (>3 μg/mL) showed 2.3× faster cognitive decline and increased CSF tau
Supports
IL-1β drives tau hyperphosphorylation via GSK-3β activation in mouse models
Supports
CRP binds to phosphocholine on apoptotic cells, activating NLRP3 inflammasome and IL-1β release
Supports
Microglial MyD88 deletion attenuates tau pathology in PS19 mice
Contradicts
Mendelian randomization studies failed to demonstrate CRP genetic variants influence AD risk
Contradicts
Canakinumab (anti-IL-1β) trials showed no cognitive benefit despite CRP reduction - CANTOS trial was definitive negative
Contradicts
NSAIDs failed in AD prevention trials and may accelerate cognitive decline
Contradicts
IL1RN polymorphisms do not show consistent association with AD risk in genome-wide studies
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — CCR2

No curated PDB or AlphaFold mapping for CCR2 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for CCR2, TLR4, IL1B from GTEx v10.

Spinal cord cervical c-10.3 Hypothalamus0.1 Substantia nigra0.1 Hippocampus0.0 Amygdala0.0 Caudate basal ganglia0.0 Cortex0.0 Putamen basal ganglia0.0 Nucleus accumbens basal ganglia0.0 Anterior cingulate cortex BA240.0 Cerebellum0.0 Frontal Cortex BA90.0 Cerebellar Hemisphere0.0median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CCR2, TLR4, IL1B →

No DepMap CRISPR Chronos data found for CCR2, TLR4, IL1B.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.6%
Volatility
Low
0.0026
Events (7d)
2
Price History
▲15.1%

💾 Resource Usage

LLM Tokens
36,998
$0.1110
Total Cost
$0.1110
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.